NCT06460493

Effect of Ensifentrine Treatment on CAT Score

A Study Assessing the Effect of Ensifentrine on CAT™ Scores Over 12 Weeks in Subjects With Moderate to Severe COPD

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Verona Pharma plc · Industry
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this open-label, single center trial is to assess the effect of twice daily nebulized ensifentrine (3 mg) on COPD symptoms measured by the COPD Assessment Test (CAT™) scores over 12 weeks in subjects with symptomatic, moderate to severe COPD, taking maintenance LAMA/LABA or LAMA/LABA/ICS therapy. Subjects will continue the maintenance treatment during study participation.

Conditions

• COPD

Interventions

Type	Name	Description
DRUG	Ensifentrine 3 mg twice daily	All subjects will receive ensifentrine.

Timeline

• Start date: 2024-06-11
• Primary completion: 2024-11-26
• Completion: 2024-12-03
• First posted: 2024-06-14
• Last updated: 2025-04-18
• Results posted: 2025-04-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study